Published in Virology on December 06, 2011
L2, the minor capsid protein of papillomavirus. Virology (2013) 1.07
The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans-Golgi network. Virology (2014) 1.00
Concepts of papillomavirus entry into host cells. Curr Opin Virol (2013) 0.93
Host-cell factors involved in papillomavirus entry. Med Microbiol Immunol (2012) 0.92
Incoming human papillomavirus type 16 genome resides in a vesicular compartment throughout mitosis. Proc Natl Acad Sci U S A (2016) 0.85
Nuclear entry of DNA viruses. Front Microbiol (2015) 0.82
A central region in the minor capsid protein of papillomaviruses facilitates viral genome tethering and membrane penetration for mitotic nuclear entry. PLoS Pathog (2017) 0.76
Furin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilins. J Virol (2016) 0.76
Coat as a dagger: the use of capsid proteins to perforate membranes during non-enveloped DNA viruses trafficking. Viruses (2014) 0.76
Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One (2017) 0.75
Incoming human papillomavirus 16 genome is lost in PML protein-deficient HaCaT keratinocytes. Cell Microbiol (2016) 0.75
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev (2004) 3.52
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A (2006) 2.64
Papillomaviruses infect cells via a clathrin-dependent pathway. Virology (2003) 2.47
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A (2004) 2.43
Arrangement of L2 within the papillomavirus capsid. J Virol (2008) 2.37
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol (2007) 2.32
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol (2006) 2.16
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Clathrin- and caveolin-independent entry of human papillomavirus type 16--involvement of tetraspanin-enriched microdomains (TEMs). PLoS One (2008) 1.63
Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol (2007) 1.59
The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J Virol (2005) 1.53
Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2. J Virol (2006) 1.53
Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J (2009) 1.36
Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. J Virol (2008) 1.36
Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett (2004) 1.35
The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. J Virol (2004) 1.30
Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J Virol (2001) 1.28
Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27
Assembly and translocation of papillomavirus capsid proteins. J Virol (2002) 1.26
Dissection of human papillomavirus type 33 L2 domains involved in nuclear domains (ND) 10 homing and reorganization. Virology (2003) 1.14
Papillomavirus infection requires gamma secretase. J Virol (2010) 1.12
Sequences required for the nuclear targeting and accumulation of human papillomavirus type 6B L2 protein. Virology (1995) 1.08
The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. J Virol (2004) 1.06
The l2 minor capsid protein of low-risk human papillomavirus type 11 interacts with host nuclear import receptors and viral DNA. J Virol (2006) 1.03
Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18. J Virol (2007) 0.97
Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol (2008) 0.92
Interaction of human papillomavirus type 16 L2 with cellular proteins: identification of novel nuclear body-associated proteins. Virology (2002) 0.90
Nuclear import strategies of high-risk HPV18 L2 minor capsid protein. Virology (2006) 0.88
Linear motif atlas for phosphorylation-dependent signaling. Sci Signal (2008) 3.77
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol (2010) 1.62
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res (2006) 1.41
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res (2008) 1.33
The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. J Virol (2004) 1.30
Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res (2006) 1.28
Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27
Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol (2009) 1.18
Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle (2012) 1.17
Nuclear import strategies of high risk HPV16 L1 major capsid protein. J Biol Chem (2002) 1.17
B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol (2005) 1.16
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Papillomavirus infection requires gamma secretase. J Virol (2010) 1.12
Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein. Virology (2008) 1.11
Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08
L2, the minor capsid protein of papillomavirus. Virology (2013) 1.07
The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. J Virol (2004) 1.06
Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res (2006) 1.06
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05
The E7 oncoprotein of high-risk human papillomavirus type 16 enters the nucleus via a nonclassical Ran-dependent pathway. Virology (2003) 1.04
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00
Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol (2009) 1.00
Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt (2010) 0.99
p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol (2009) 0.99
Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol (2011) 0.97
Possible role for cellular karyopherins in regulating polyomavirus and papillomavirus capsid assembly. J Virol (2008) 0.97
Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol (2007) 0.96
Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res (2013) 0.96
Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics (2011) 0.96
Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95
The L1 major capsid protein of human papillomavirus type 11 interacts with Kap beta2 and Kap beta3 nuclear import receptors. Virology (2003) 0.95
Role of L2 cysteines in papillomavirus infection and neutralization. Virol J (2009) 0.95
Nuclear entry of high-risk human papillomavirus type 16 E6 oncoprotein occurs via several pathways. J Virol (2003) 0.93
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol (2008) 0.92
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92
Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol (2010) 0.92
ETS-domain transcription factor Elk-1 mediates neuronal survival: SMN as a potential target. Biochim Biophys Acta (2011) 0.91
Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology (2012) 0.89
Nuclear localization of Kaiso promotes the poorly differentiated phenotype and EMT in infiltrating ductal carcinomas. Clin Exp Metastasis (2014) 0.87
Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One (2011) 0.87
The future of vaccines for cervical cancer. Gynecol Oncol (2008) 0.87
Characterization of the nuclear localization signal of high risk HPV16 E2 protein. Virology (2006) 0.87
The nuclear localization of low risk HPV11 E7 protein mediated by its zinc binding domain is independent of nuclear import receptors. Virology (2010) 0.86
De novo discovery of serotonin N-acetyltransferase inhibitors. J Med Chem (2007) 0.86
Immunohistochemical detection of human papillomavirus capsid proteins L1 and L2 in squamous intraepithelial lesions: potential utility in diagnosis and management. Mod Pathol (2012) 0.85
Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J Immunol (2004) 0.85
Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs (2004) 0.85
Characterization of the transport signals that mediate the nucleocytoplasmic traffic of low risk HPV11 E7. Virology (2013) 0.84
Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. PLoS One (2013) 0.84
Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. PLoS One (2013) 0.83
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83
HPV pseudovirions as DNA delivery vehicles. Ther Deliv (2011) 0.83
The function, proteolytic processing, and histopathology of Met in cancer. Adv Cancer Res (2009) 0.82
Nuclear import of high risk HPV16 E7 oncoprotein is mediated by its zinc-binding domain via hydrophobic interactions with Nup62. Virology (2013) 0.81
Vaccines against human papillomavirus. Front Biosci (2007) 0.76
A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology (2011) 0.76
GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. Am J Surg Pathol (2015) 0.75